Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
SBCH: Malt powered performance - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Jul 27, 2001

    SBCH: Malt powered performance

    Malted beverage major, SmithKline Beecham Consumer Healthcare (SBCH), has posted impressive growth in the second quarter. In 2QFY02, the company has declared a 45% growth in bottomline. What is even more interesting is that its topline has shown a growth of 17.5%.

    (Rs m) 2QFY01 2QFY02 Change 1HFY01 1HFY02 Change
    Net sales 1,805 2,121 17.5% 3,531 4,273 21.0%
    Other Income 55 70 27.1% 165 153 -7.3%
    Expenditure 1,465 1,627 11.1% 2,932 3,374 15.1%
    Operating Profit (EBDIT) 341 494 45.1% 600 900 50.1%
    Operating Profit Margin (%) 18.9% 23.3%   17.0% 21.1%  
    Interest (net) 14 (8)   36 16 -56.3%
    Depreciation 36 34 -5.3% 73 67 -8.2%
    Profit before Tax 346 538 55.6% 656 970 47.9%
    Tax 68 135 99.4% 152 257 69.6%
    Extraordinary expenses         24  
    Profit after Tax/(Loss) 278 403 44.9% 504 688 36.6%
    Net profit margin (%) 15.4% 19.0%   14.3% 16.1%  
    No. of Shares (eoy) (m) 45.4 45.4   45.4 45.4  
    Diluted Earnings per share* 24.5 35.5   22.2 30.3  
    Current P/e ratio   12.2     14.3  

    However, the relatively high growth percentage in sales clocked in 2QFY02 should be reviewed against last year's reported results for the corresponding period, which were influenced by subdued trading.

    SBCH improved its operating margins by a significant 440 basis points. Its advertising expenses declined by 12% during the quarter to Rs 152 m. This and a 27% jump in other income helped the company post an impressive 45% growth in bottomline, despite the tax provisioning nearly doubling.

    On a consolidated half yearly basis, SBCH's topline has grown by 21% and its bottomline by 37%. The performance indicates the stability of SBCH's growth.

    On the current price of Rs 435 the stock trades at a P/e multiple of 15 times our projected earnings for FY02. The company's market cap to sales comes to about 2.3 times. The stock has already risen 10% since its 1QFY02 results. Going forward, the stock is likely to see a further upside based on the company's attractive valuations.



    Equitymaster requests your view! Post a comment on "SBCH: Malt powered performance". Click here!


    More Views on News

    GSK Consumer: On the Recovery Path (Quarterly Results Update - Detailed)

    Jun 20, 2017

    While GSK consumer reported muted revenue growth, volumes are seen to be recovering.

    GSK Consumer: Price Hike Hurts Volumes (Quarterly Results Update - Detailed)

    Nov 30, 2016

    GSK Consumer Healthcare declared results for the quarter ended September 2016. The revenues dropped by 1.3% during the quarter as compared to a year ago; while the profits declined by 16.6% YoY during the quarter.

    GSK Consumer: Slowdown in demand impacts sales (Quarterly Results Update - Detailed)

    Oct 5, 2016

    GSK Consumer Healthcare has announced the first quarter results of the financial year 2016-2017 (1QFY17). The company's sales declined by 1.4% YoY while net profit rose by 2.9% YoY during the quarter.

    GSK Consumer: A Forgetful Year (Quarterly Results Update - Detailed)

    Jun 1, 2016

    GSK Consumer Healthcare announced its results for the quarter and year ended March 2016. During the quarter, sales and profit came in lower by 9% YoY and 8% YoY respectively.

    GSK Consumer: Feeling the Growth Pressures? (Quarterly Results Update - Detailed)

    Feb 15, 2016

    GSK Consumer Healthcare announced its results for the quarter ended December 2015. While revenues were up by 2% YoY, profits were higher by 37% YoY.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 18, 2017 (Close)


    • Track your investment in GSK CONSUMER with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks


    Detailed Financial Information With Charts